WASHINGTON, D.C. — Two bills aimed at renewing the Small Business Innovation Research (SBIR) grant program are at odds about how much grant money companies that have received venture capital investments should be able to get.
One bill to renew the SBIR program was unanimously passed by the House Committee on Small Business on Thursday, according to the Wall Street Journal’s Capital Venture Dispatch blog. The House bill is friendlier to venture capitalists and their portfolio companies than a bill moving through the Senate, the Journal blog has said previously.
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
The House bill would reverse a Small Business Administration policy in place since 2003 that keeps venture-backed firms from getting SBIR funding, the blog said. Under this bill, grant amounts from the SBIR program and from its sister program, the Small Business Technology Transfer (STTR) program, would not be capped when awarded to companies in which venture capital firms have invested.
The Senate version of the bill, which is awaiting a floor vote, proposes an 8 percent cap for each federal agency that provides SBIR funding except for the Department of Health and Human Services, which has proposed a cap of 18 percent.
The House bill does include some restrictions to insure that truly small businesses continue to get the research and technology grants.
“Perhaps most importantly, the legislation restores the pre-2003 eligibility rules permitting small businesses with venture capital investment to qualify for SBIR awards,” Rep. Nydia Velazquez, the New York Democrat who chairs the House small business committee, told the Wall Street Journal.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Life sciences interests have largely supported expanding SBIR/STTR funding to include venture-backed companies. However, some smaller biotech companies — especially Midwest companies that tend to get less venture capital investment than those in New York and California — see the expansion as a potential death knell for small business and innovation funding.
More stories worth a read:
- St. Vincent Charity Hospital in Cleveland opens larger emergency department (Cleveland Plain Dealer)
- Cuyahoga Health Access Partnership threatened by hospitals’ reluctance to commit resources (Cleveland Plain Dealer)
- Bringing nurses back: As people hit refresh button on their careers, nursing wins (Business Courier of Cincinnati)
- Baiju Shah leads a BioEnterprise team helping build Northeast Ohio’s biomedical industry (Cleveland Plain Dealer)
- Ex-Browns Jurevicius sues team, Cleveland Clinic over staph infection (Associated Press/BrewCityBuck)
- Antibiotic resistance has become a legal issue (Mike the Mad Biologist blog)
- Jackson’s death focuses attention on cardiac death (Forbes)
- University of Pittsburgh Medical Center moves to expand presence in Ireland with investment (Pittsburgh Business Times)
- Health-data firms chase stimulus sales (Minneapolis/St. Paul Business Journal)
- Biomarkers gain ground in fight to rein in drug costs (Boston Business Journal)
- University of Tennessee Health Science Center plans to build $50 million research center (Memphis Business Journal)
- Much talk, little action on Ohio budget (Columbus Dispatch)
- Paramedics move to the front: Tactical team begun in order to get EMS closer to the action (Columbus Dispatch)
- Sanofi-Aventis eyes acquisition trail (Financial Times)